Citations

Clear

1727 citation(s) found for "Fu, Alan".

Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.
Michalski, Jeff M. , Pisansky, Thomas M. , Pollack, Alan , Zietman, Anthony L., Stephans, Kevin L. , Gao, Tianming, Stephenson, Andrew J. , Tendulkar, Rahul D. , Agrawal, Shree , Efstathiou, Jason A. , Koontz, Bridget F. , Liauw, Stanley L. , Abramowitz, Matthew C. , Anscher, Mitchell S. , Moghanaki, Drew M. , Den, Robert B. , Lee, W. Robert , Hearn, Jason W.D. , Spratt, Daniel E. , Kattan, Michael W.

Mayo Clinic

Journal of Clinical Oncology | April 9, 2018 | Volume: 2017 | Issue: 1_suppl | Pages: 9-9

10.1200/jco.2017.35.6_suppl.9.2017.1.test Get It

Irreversible electroporation for the treatment of cardiac arrhythmias
Sugrue, Alan , Maor, Elad , Ivorra, Antoni , Vaidya, Vaibhav R. , Witt, Chance M. , Asirvatham, Samuel J. , Vaidya, Vaibhav, Witt, Chance, Kapa, Suraj , Asirvatham, Samuel J , Maor, Elad

Mayo Clinic

Expert Review of Cardiovascular Therapy | March 29, 2018 | Volume: 16 | Issue: 5 | Pages: 349-360

10.1080/14779072.2018.1459185 | PMID 29595355 Get It

Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter‐Defibrillators in the Cardiovascular Research Network
Greenlee, Robert T. , Go, Alan S. , Peterson, Pamela N., Gaber, Charles , Garcia‐Montilla, Romel , Glenn, Karen A., Gupta, Nigel, Gurwitz, Jerry H. , Hammill, Stephen C., Hayes, John J., Kadish, Alan H. , Magid, David J. , McManus, David D. , Multerer, Deborah, Powers, J. David , Reifler, Liza M. , Schuger, Claudio , Sharma, Param , Smith, David H. , Suits, Mary, Sung, Sue Hee, Varosy, Paul D. , Vidaillet, Humberto, Masoudi, Frederick A. , Peterson, Pamela N. , Cassidy‐Bushrow, Andrea E. , Reynolds, Kristi

Mayo Clinic

Journal of the American Heart Association | March 26, 2018 | Volume: 7 | Issue: 7 | Pages: No page available

10.1161/jaha.117.008292 | PMID 29581222 Get It

Background Primary prevention implantable cardioverter‐defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems. Methods and Results We linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection fraction, 31% to 35%; nonischemic cardiomyopathy <9 months’ duration; and New York Heart Association class IV heart failure with cardiac resynchronization therapy defibrillator. Among 2540 patients, 35% were <65 years old, 26% were women, and 59% were white. During 27 (median) months, 738 (29%) received ≥1 therapy. Three‐year therapy risk was 36% (appropriate, 24%; inappropriate, 12%). Appropriate therapy was more common in men (adjusted hazard ratio [HR], 1.84; 95% confidence interval [CI], 1.43–2.35). Inappropriate therapy was more common in patients with atrial fibrillation (adjusted HR, 2.20; 95% CI, 1.68–2.87), but less common among patients ≥65 years old versus younger (adjusted HR, 0.72; 95% CI, 0.54–0.95) and in recent implants (eg, in 2009 versus 2006; adjusted HR, 0.66; 95% CI, 0.46–0.95). In Centers for Medicare and Medicaid Services Coverage With Evidence Development analysis, inappropriate therapy was less common with cardiac resynchronization therapy defibrillator versus single chamber (adjusted HR, 0.55; 95% CI, 0.36–0.84); therapy risk did not otherwise differ for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups. Conclusions In this community cohort of primary prevention patients receiving ICD, therapy delivery varied across demographic and clinical characteristics, but did not differ meaningfully for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups.
Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
Brennan, Alan , Hatswell, Anthony J. , Porter, J. , Sapra, Sandhya, Villa, Guillermo , Shah, Neel , Tepper, Stewart J. , Dodick, David, Lipton, Richard B. , Palmer, Stephen , Dodick, David W.

Mayo Clinic

Journal of Medical Economics | March 24, 2018 | Volume: 21 | Issue: 7 | Pages: 666-675

10.1080/13696998.2018.1457533 | PMID 29571276 Get It

Risk of Dental Implant Failure Associated With Medication Use
Revuru, Venkata, Lohse, Christine M. , Carr, Alan B. , Revuru, Venkata S

Mayo Clinic

Journal of Prosthodontics | March 6, 2018 | Volume: 28 | Issue: 7 | Pages: 743-749

10.1111/jopr.12773 | PMID 29508502 Get It

AbstractPurposeThe probability of achieving important clinical outcomes is an increasingly important factor for patients considering various treatment options for tooth loss. For oral reconstruction involving dental implants, the patient‐specific risks of implant failure may be influenced by the patient's medication profile. The purpose of this study was to identify associations between dental implant failure and medication use in a consecutive series of patients seen from October 1983 through December 2014 at the Department of Dental Specialties, Mayo Clinic (Rochester, Minnesota).Materials and MethodsIn this patient‐level analysis, demographic, implant‐specific, and medical profile data were abstracted from a prospective clinical database and individual medical records and used to determine the time to first implant failure. Implant failure‐free survival at the patient level was estimated using the Kaplan‐Meier method. Associations of demographic characteristics and medication use with implant failure were evaluated by using Cox proportional hazards regression models and summarized with hazard ratios and 95% confidence intervals.ResultsIn the 31‐year study period, 6358 patients received their first dental implant (median age, 53 years). The median follow‐up duration of the 5645 patients whose implants did not fail was 5.8 years, and 713 patients had implant failure (median, 0.6 years). All associations were adjusted for age, sex, and era of implantation because these features strongly influence medication use and implant failure. After adjustment, no medication increased the risk of implant failure in the cohort; specifically, medication use at the time of implant placement or starting a medication after implant placement did not increase the risk of implant failure. Among the medications used at the time of implant placement, corticosteroids were associated with a reduced risk of implant failure (hazard ratio, 0.82; 95% CI, 0.67‐0.99; p = 0.04). This association was not seen when corticosteroids were started after implant placement.ConclusionIn the population studied, medication use was not associated with an increased risk of dental implant failure.
An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, Sarah J. , Cappola, Anne Rentoumis , Castro, M. Regina , Dayan, Colin , Hennessey, James V. , Kopp, Peter , Ross, Douglas S. , Samuels, Mary H. , Sawka, Anna M. , Taylor, Peter , Jonklaas, Jacqueline , Bianco, Antônio C. , Taylor, Peter N , Farwell, Alan Perry

Mayo Clinic

Thyroid | March 3, 2018 | Volume: 28 | Issue: 6 | Pages: 707-721

10.1089/thy.2017.0681 | PMID 29620972 Get It

Normal values for assessment of anal sphincter morphology, anorectal motion, and pelvic organ prolapse with MRI in healthy women
Tirumanisetty, Pratyusha , Prichard, David O. , Zinsmeister, Alan R., Bharucha, Adil E. , Bharucha, A E , Fletcher, Joel G. , Chakraborty, Sumit

Mayo Clinic

Neurogastroenterology & Motility | March 2, 2018 | Volume: 30 | Issue: 7 | Pages: No page available

10.1111/nmo.13314 | PMID 29498141 Get It

AbstractBackgroundEndoanal MRI and MR defecography are used to identify anal sphincter injury and disordered defecation. However, few studies have evaluated findings in asymptomatic healthy people. The effects of BMI and parity on rectoanal motion and evacuation are unknown.MethodsIn 113 asymptomatic females (age 50 ± 17 years, Mean ± SD) without risk factors for anorectal trauma, anal sphincter appearance, anorectal motion, and pelvic organ prolapse were evaluated with MRI. The relationship between age, BMI, and parity and structural findings were evaluated with parametric and non‐parametric tests.ResultsThe anal sphincters and puborectalis appeared normal in over 90% of women. During dynamic MRI, the anorectal angle was 100 ± 1º (Mean ± SEM) at rest, 70 ± 2° at squeeze, and 120 ± 2° during defecation. The change in anorectal angle during squeeze (r = −.25, P < .005), but not during evacuation (r = .13, P = .25) was associated with age. In the multivariable models, BMI (P < .01) and parity (P < .01) were, respectively, independently associated with the intersubject variation in the anorectal angle at rest and the angle change during squeeze. Ten percent or fewer women had had descent of the bladder base or uterus 4 cm or more below the pubococcygeal line or a rectocele measuring 4 cm or larger. Only 5% had a patulous anal canal.ConclusionsIn addition to age, BMI and parity also affect anorectal motion in asymptomatic women. These findings provide age‐adjusted normal values for rectoanal anatomy and pelvic floor motion.
A2 GATHERING AND ASSESSING EVIDENCE TO INFORM A GUIDELINE ON SCREENING FOR COLORECTAL CANCER IN INDIVIDUALS WITH A FAMILY HISTORY
Leddin, Desmond , Tse, F, Samadder, N. Jewel , Tinmouth, Jill , Abou-Setta, Ahmed M , Lieberman, David A. , Leontiadis, Grigorios I. , Barkun, Alan , Marshall, John K. , Singh, Harminder , Telford, Jennifer J. , Wilkinson, Anna N.

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 1, 2018 | Volume: 1 | Issue: suppl_2 | Pages: 2-2

10.1093/jcag/gwy009.002 Get It

Allelic variant in the glucagon‐like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study
Chedid, Victor , Vijayvargiya, Prakhar , Carlson, Paula, Malderen, Kathleen Van , Zinsmeister, Alan R., Camilleri, Michael , Camilleri, M , Chedid, Victor G , Acosta, Andrés

Mayo Clinic

Neurogastroenterology & Motility | February 28, 2018 | Volume: 30 | Issue: 7 | Pages: No page available

10.1111/nmo.13313 | PMID 29488276 Get It

AbstractBackgroundWeight loss in response to the long‐acting GLP‐1 receptor (GLP1R) analog, liraglutide, is correlated with delay in gastric‐emptying (GE). The aim of this pilot study was to assess whether specific genetic variants in GLP1R or TCF7L2 are associated with delayed GE and weight loss in obese patients treated with liraglutide or the short‐acting GLP‐1 agonist, exenatide.MethodsWe evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5 μg BID for 30 days, or liraglutide, 3 mg daily for 5 weeks. Data were analyzed using the dominant genetic model and intention‐to‐treat analysis.Key ResultsThere was a significant correlation between changes in weight and GE T1/2 (rs = −.382, P = .004). GLP1R rs6923761 minor allele A (AA_AG) carriers who received either exenatide or liraglutide had greater delay in GE T1/2 relative to baseline (117.9 ± 27.5 [SEM] minutes and 128.9 ± 38.32 minutes) compared to GG genotype (95.8 ± 30.4 minutes and 61.4 ± 21.4 minutes, respectively; P = .11). There was a non‐significant difference in weight loss based on GLP1R rs6923761 genotype after 5 weeks of treatment. There were no significant correlations with TCF7L2 (rs7903146) genotype.Conclusions & InferencesThe minor A allele of GLP1R (rs6923761) is associated with greater delay in GE T1/2 in response to liraglutide and exenatide. These studies provide data to plan pharmacogenetics testing of the hypothesis that GLP1R (rs6923761) influences weight loss in response to GLP1R agonists.
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficien
Ryan, Charles J. , Abida, Wassim , Dumbadze, Igor, Given, Robert , Petrylak, Daniel P. , Redfern, Charles H., Scher, Howard I. , Watkins, Simon P. , Simmons, Andrew D. , Passler, Luke, Golsorkhi, Tony, Chowdhury, Simon, Watkins, Simon P , Bryce, Alan H. , Balar, Arjun Vasant , Morris, David S. , Passler, Luke

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS389-TPS389

10.1200/jco.2018.36.6_suppl.tps389 Get It

TPS389 Background: Recent data have shown that up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM, or another homologous recombination DNA repair gene. Such mutations can be used as a molecular marker to select patients for targeted treatment with poly(ADP-ribose) polymerase inhibitors (PARPis), which are lethal to cells with HRD. Treatment with PARPis has shown preliminary evidence of antitumor activity in patients with mCRPC and a mutation in a homologous recombination DNA repair gene (Mateo et al. N Engl J Med. 2015;373:1697-708). These data provide a compelling rationale for evaluating rucaparib, a potent inhibitor of PARP1, PARP2, and PARP3, in patients with mCRPC associated with HRD. Methods: TRITON3 (NCT02975934) is a randomized, phase 3 study evaluating rucaparib 600 mg BID vs physician’s choice of abiraterone, enzalutamide, or docetaxel in patients with mCRPC and a deleterious germline or somatic BRCA1, BRCA2, or ATM mutation (identified by prior local testing or central testing during screening). Patients must have progressed on androgen receptor signaling–directed therapy in the mCRPC setting; prior PARPi treatment or chemotherapy for mCRPC are exclusion criteria. Patients will be randomly assigned in a 2:1 ratio to either rucaparib or physician’s choice, with the possibility for cross over from the comparator treatment to rucaparib upon radiographic progression confirmed by independent radiology review. The primary endpoint is radiographic progression-free survival (modified RECIST v1.1/PCWG3 criteria) assessed by independent radiology review. Secondary endpoints include objective response rate, duration of response, patient-reported outcomes, overall survival, and safety. Pretreatment blood samples collected from all patients will enable development of a noninvasive plasma-based companion diagnostic to select patients who may benefit from rucaparib treatment. Patients (≈400) will be enrolled at > 100 sites worldwide. Clinical trial information: NCT02975934.